The company, Nucleus RadioPharma, will create the following technologies to ensure cancer patients can access potentially life-saving radiopharmaceuticals, according to an Oct. 12 press release from Nucleus.
Radiopharmaceuticals expert Charles Conroy will be CEO of the company and Manu Nair, chair of corporate development at Mayo Clinic, will join the company’s board of directors.
The company currently has $6 million in seed funding, and aims “to bring [radiopharmaceutical] treatments to the market at a cost, scale and efficacy that will impact millions of lives,” according to the release.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
